The preliminary results of these trials provide important evidence for the use of TIM-3 monoclonal antibody in MDS: in combination with demethylating drugs, it can enhance the response of high-risk MDS patients to a certain extent and is well tolerated, bringing new therapeutic hope for MDS patients. Here, HAVCR2 is linked to myelodysplastic syndrome.